WCN26-3583 A Preliminary Study on the Outcomes of Multidisciplinary Pharmaceutical Care for Patients with Chronic Kidney Disease

Read full text Summarise with VIRAT
Authors: Ling-Yi Huang, Shi-Yun Huang
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

According to the International Society of Nephrology's Kidney Health Atlas, the prevalence of chronic kidney disease (CKD) in Taiwan has increased from 12.2% in 2019 to 16.3%. The 2024 Taiwan Society of Nephrology Kidney Disease Annual Report indicates a slight decline in the age-standardized dialysis incidence rate since 2018, from 309 per million population in 2019 to 289 in 2021 and 290 in 2022. Despite this mild decrease, the absolute number of dialysis cases continues to rise. In 2022, outpatient and emergency medical expenses for end-stage renal disease (ESRD) reached NT$70.26 billion, accounting for 10.5% of Taiwan's total National Health Insurance (NHI) expenditure –an increase of approximately 1% from 2021 –thus posing a substantial financial burden on the healthcare system.

Fields of Study & Subjects

Dialysis and Renal Disease Management Pharmacy and Medical Practices Pharmaceutical Practices and Patient Outcomes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104742–104742
Publication date
25 March 2026
Language
EN